Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 16/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 15/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 15/20 | 0.45 |
| ▸ | PRKDC | P78527 | 15/20 | 0.45 |
| ▸ | ABL1 | P00519 | 13/20 | 0.45 |
| ▸ | EGFR | P00533 | 13/20 | 0.45 |
| ▸ | HCK | P08631 | 13/20 | 0.45 |
| ▸ | SRC | P12931 | 13/20 | 0.45 |
| ▸ | MTOR | P42345 | 13/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 13/20 | 0.45 |
| ▸ | KDR | P35968 | 12/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.45 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23917543 | 0.81 | PIK3CD (0.44) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL23917544 | 0.81 | PIK3CD (0.44) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL23917261 | 0.80 | EIF2AK3 (0.37) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL16655665 | 0.79 | PIK3CD (0.58) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL16665791 | 0.77 | MTOR (0.34) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL18065759 | 0.75 | PIK3CD (0.42) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL16702703 | 0.74 | BTK (0.44) | PIK3CDPIK3CGEGFR | |
| SCHEMBL23917284 | 0.74 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL16665717 | 0.74 | RET (0.33) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC | |
| SCHEMBL16701825 | 0.73 | BTK (0.37) | PIK3CDPIK3CGPIK3CAPIK3CBPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CG 8/4885PIK3CA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.